Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06207123 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

A Phase 1 study of Acute Leukemia and Lymphoblastic Lymphoma, sponsored by University of Chicago.

Recruiting
Registry status
Phase 1
Development phase
15
Enrollment target
2
Study locations

NCT06207123: Recruiting Phase 1 study of Acute Leukemia and Lymphoblastic Lymphoma, sponsored by University of Chicago.

NCT06207123 is a Phase 1 study of Acute Leukemia and Lymphoblastic Lymphoma that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 15 participants, below the 463-participant average among 37 other Acute Leukemia trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06207123, a Phase 1 study of Acute Leukemia and Lymphoblastic Lymphoma, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphoblastic leukemia.

Conditions Studied

Acute Leukemia Lymphoblastic Lymphoma Lymphoblastic Leukemia

Interventions

  • DRUG Dexamethasone
  • DRUG Vincristine
  • DRUG Methotrexate
  • DRUG Ponatinib
  • DRUG LP-118

Study Locations (2)

Illinois

  • University of Chicago Medicine Comprehensive Cancer Center - Chicago

New York

  • University of Rochester Medical Center, Wilmot Cancer Center - Rochester

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-09-13
Est. Completion 2026-12-01
Phase Phase 1

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06207123

The ClinicalTrials.gov registry entry for NCT06207123 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 463-participant average among 37 other Acute Leukemia trials with a reported enrollment target (97% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Acute Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.

NCT06207123 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, New York.

Frequently Asked Questions

What is clinical trial NCT06207123 about?

NCT06207123 is a clinical study titled "A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)". The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphobl...

What is the current status of trial NCT06207123?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-09-13. Estimated completion is 2026-12-01.

What conditions does trial NCT06207123 study?

This clinical trial studies the following conditions: Acute Leukemia, Lymphoblastic Lymphoma, Lymphoblastic Leukemia.

What interventions are being tested in trial NCT06207123?

The interventions under investigation include: Dexamethasone (DRUG), Vincristine (DRUG), Methotrexate (DRUG), Ponatinib (DRUG), LP-118 (DRUG).

Who is sponsoring clinical trial NCT06207123?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06207123 being conducted?

This trial has 2 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Leukemia

All registered trials for this condition

Lymphoblastic Lymphoma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.